Maximum quantity allowed is 999
Please select the quantity
CAS RN: 137862-53-4 | Product Number: V0112
Valsartan
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- N-Valeryl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-L-valine
Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 1G |
£22.00
|
2 | ≥20 |
|
| 5G |
£74.00
|
2 | ≥20 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | V0112 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__4H__2__9N__5O__3 = 435.53 |
| Physical State (20 deg.C) | Solid |
| CAS RN | 137862-53-4 |
| Reaxys Registry Number | 7754038 |
| PubChem Substance ID | 125307697 |
| SDBS (AIST Spectral DB) | 52923 |
| Merck Index (14) | 9916 |
| MDL Number | MFCD00865840 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Specific rotation [a]20/D | -63.0 to -67.0 deg(C=1, methanol) |
Properties (reference)
| Melting Point | 117 °C |
| Specific Rotation | -65° (C=1,MeOH) |
| Solubility (soluble in) | Methanol |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H361 : Suspected of damaging fertility or the unborn child. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P405 : Store locked up. |
Related Laws:
| RTECS# | YV9455000 |
Transport Information:
| HS Number | 2933998090 |
Application
Valsartan: A Competitive and Selective AT1 Receptor Antagonist
Valsartan is a competitive and selective AT1 receptor antagonist. Valsartan inhibits the actions of angiotensin II at the AT1 receptor subtype which is responsible for most of the known effects of angiotensin II, a principal pressor agent. Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE). Valsartan blocks the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle. Recently, the combination of valsartan and a thiazide diuretic hydrochlorothiazide [H1274] is often use in clinical. (The product is for research purpose only.)
References
- Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype
- Expression, secretion, and inhibition of angiotensin-converting enzyme in cultured human bronchial epithelial cells
- Valsartan: a review of its pharmacology and therapeutic use in essential hypertension
- Valsartan: more than a decade of experience (a review)
- Valsartan/hydrochlorothiazide. A review of its pharmacology, therapeutic efficacy and place in the management of hypertension
PubMed Literature
Documents
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number is entered
Analytical Charts
Please enter Lot Number
Incorrect Lot Number is entered
The requested Analytical Chart is not available.